Nitrase Therapeutics Announces Publication in the Journal of Biological Chemistry on the Role of Tyrosine Nitration in Cell Signaling and Cancer Biology
July 13, 2023 08:00 ET
|
Nitrase Therapeutics
BRISBANE, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, a new...
Nitrase Therapeutics Presents Preclinical Data on the Role of Enzymatic Nitration in Oncology at the American Association for Cancer Research Annual Meeting
April 18, 2023 16:00 ET
|
Nitrase Therapeutics
BRISBANE, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, a new...
Nitrase Therapeutics Presented New Findings on the Role of Synuclein Nitrase in Alpha Synuclein Nitration and Aggregation, as well as Motor Dysfunction at the 2023 Alzheimer's & Parkinson's Diseases (AD/PD) Conference
March 28, 2023 08:00 ET
|
Nitrase Therapeutics
BRISBANE, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, a new...
Nitrase Therapeutics to Present at the 2023 American Association for Cancer Research Annual Meeting
March 14, 2023 16:30 ET
|
Nitrase Therapeutics
BRISBANE, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, a new...
Nitrase Therapeutics Presented Data on the Importance of Synuclein Nitrase on the Synaptic Activity of Differentiated Dopaminergic Neurons at the Society for Neuroscience (SFN) Conference
November 14, 2022 08:00 ET
|
Nitrase Therapeutics
-Data Elucidate Role of Company-identified Enzyme, Synuclein Nitrase, in Parkinson’s Disease- BRISBANE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical...
Nitrase Therapeutics Presented Data on Role of Novel Nitrases in Regulating Known and Important Cancer Targets at EORTC-NCI-AACR Symposium
October 31, 2022 08:00 ET
|
Nitrase Therapeutics
BRISBANE, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, a new...
Nitrase Therapeutics Appoints Arun Kashyap, Ph.D., to Lead its Recently Launched Oncology Programs as Senior Vice President of Oncology
September 07, 2022 08:00 ET
|
Nitrase Therapeutics
BRISBANE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, a new...
Nitrase Therapeutics Expands Leadership Team with Accomplished Drug Discovery and Development Executives
July 06, 2022 08:00 ET
|
Nitrase Therapeutics
SAN FRANCISCO, July 06, 2022 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its unique NITROME platform to unlock the therapeutic potential of nitrases, a new...
Nitrase Therapeutics Expands Pipeline to Include Oncology Programs and Adds Seasoned Cancer Experts to Scientific Advisory Board
June 02, 2022 08:00 ET
|
Nitrase Therapeutics
BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its unique NITROME platform to unlock the therapeutic potential of nitrases, a...
Nitrase Therapeutics Receives New Grant from The Michael J. Fox Foundation for Parkinson’s Research
April 05, 2022 08:00 ET
|
Nitrase Therapeutics
BRISBANE, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its unique NITROME platform to unlock the therapeutic potential of nitrases, a...